{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:40:30Z","timestamp":1793086830502,"version":"4.5.0"},"reference-count":55,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"unspecified","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","award":["2024-0155"],"award-info":[{"award-number":["2024-0155"]}],"id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024075","name":"Region Syddanmark","doi-asserted-by":"publisher","award":["2024-0224"],"award-info":[{"award-number":["2024-0224"]}],"id":[{"id":"10.13039\/501100024075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Regionernes Medicin og Behandlingspulje","award":["EMN-2020-00001-1564745"],"award-info":[{"award-number":["EMN-2020-00001-1564745"]}]},{"DOI":"10.13039\/501100004836","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","award":["10.46540\/2096-00148B"],"award-info":[{"award-number":["10.46540\/2096-00148B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,10,10]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biologic therapies, such as vedolizumab (VDZ) and ustekinumab (UST), offer effective treatment options for inflammatory bowel disease. In spite of limited evidence, it is common practice to escalate the dosing regimen if clinical symptoms or biomarkers give suspicion of loss of response. This study aims to determine whether model-informed precision dosing (MIPD) can provide equal efficacy and possibly superior cost-effectiveness compared with symptom-based management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study is an unblinded, randomised controlled trial, conducted at six centres in Denmark. A total of 166 patients diagnosed with Crohn\u2019s disease or ulcerative colitis who have been on stable VDZ or UST therapy for at least 3\u2009months will be enrolled. Participants will be randomised to receive either continued symptom and biomarker-based dosing (control group) or dosing guided by therapeutic drug monitor using pharmacokinetic (PK) models together with PK-pharmacodynamic targets (=MIPD; intervention group). The primary endpoint is the fraction of patients in steroid-free remission at the end of the observation period. Secondary endpoints include mucosal healing, clinical remission, biochemical disease control, PK assessment and cost-effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The trial has been approved by the Danish Medicines Agency and The Medical Research Ethics Committee. No study-related procedures will take place before patients have signed written informed consent. Results will be published in peer-reviewed journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      EUCT, 2024-517123-39-00;\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06788340\">NCT06788340<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-001985","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T05:05:19Z","timestamp":1766725519000},"page":"e001985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT)"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06788340","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6639-0979","authenticated-orcid":false,"given":"Camilla","family":"Frimor","sequence":"first","affiliation":[{"name":"Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-4212","authenticated-orcid":false,"given":"Casper","family":"Steenholdt","sequence":"additional","affiliation":[{"name":"Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7069-3863","authenticated-orcid":false,"given":"Ella Signe Kassandra","family":"Widigson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin Institut f\u00fcr Pharmazie, Berlin, Germany"},{"name":"Graduate Research Training Program PharMetrX (Pharmacometrics and Computational Disease Modelling), Freie Universit\u00e4t Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-6572","authenticated-orcid":false,"given":"Jens","family":"Kjeldsen","sequence":"additional","affiliation":[{"name":"Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Aalborg Universitetshospital, Aalborg, Denmark"},{"name":"Center of Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Aalborg Universitet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Gastro Unit Medical Division, Hvidovre Hospital Gastro Unit, Hvidovre, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1874-0012","authenticated-orcid":false,"given":"Maiken Thyregod","family":"Joergensen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Vejle Hospital, Vejle, Region Syddanmark, Denmark"},{"name":"Department of Clinical Medicine, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Lee","family":"Halling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Esbjerg Central Hospital, Esbjerg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kloft","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Biochemistry, Freie Universit\u00e4t Berlin Institut f\u00fcr Pharmazie, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4899-1048","authenticated-orcid":false,"given":"Mark Andrew","family":"Ainsworth","sequence":"additional","affiliation":[{"name":"Department of Medical Gastrointestinal Diseases, Odense University Hospital, Odense, Denmark"},{"name":"Department of Clinical Research, University of Southern Denmark Faculty of Health Sciences, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2025122521050961000_12.1.e001985.1","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-013-0315-7","article-title":"Deep remission in inflammatory bowel disease: looking beyond symptoms","volume":"15","author":"Zallot","year":"2013","journal-title":"Curr Gastroenterol Rep"},{"key":"2025122521050961000_12.1.e001985.2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab029"},{"key":"2025122521050961000_12.1.e001985.3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/apt.18294","article-title":"Review article: Novel therapies in inflammatory bowel disease - An update for clinicians","volume":"60","author":"Noor","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907607"},{"key":"2025122521050961000_12.1.e001985.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1209614"},{"key":"2025122521050961000_12.1.e001985.6","doi-asserted-by":"crossref","unstructured":"Zhao M , Larsen L , Dige A , et al . Clinical Outcomes After First-Line Anti- Tumor-Necrosis-Factor Treatment of Patients With Inflammatory Bowel Disease\u2014A Prospective Multicenter Cohort Study. J Crohns Colitis 2025;19. doi:10.1093\/ecco-jcc\/jjae192","DOI":"10.1093\/ecco-jcc\/jjae192"},{"key":"2025122521050961000_12.1.e001985.7","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/1751-2980.12940","article-title":"Biosimilars in inflammatory bowel disease","volume":"21","author":"Talathi","year":"2020","journal-title":"J Dig Dis"},{"key":"2025122521050961000_12.1.e001985.8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001396"},{"key":"2025122521050961000_12.1.e001985.9","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v30.i22.2902","article-title":"Approach to loss of response to advanced therapies in inflammatory bowel disease","volume":"30","author":"Vootukuru","year":"2024","journal-title":"World J Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn\u2019s Disease","volume":"19","author":"Ollech","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/ibd\/izae140","article-title":"Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous Vedolizumab","volume":"31","author":"Porth","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025122521050961000_12.1.e001985.12","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/ibd\/izae231","article-title":"Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease","volume":"31","author":"Porth","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025122521050961000_12.1.e001985.13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/17474124.2024.2409300","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: recent developments","volume":"18","author":"Roblin","year":"2024","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2049","article-title":"Perspectives on Model-Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations","volume":"109","author":"Kluwe","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.15","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"2025122521050961000_12.1.e001985.16","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.clinthera.2022.08.010","article-title":"Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn\u2019s Disease","volume":"44","author":"Adedokun","year":"2022","journal-title":"Clin Ther"},{"key":"2025122521050961000_12.1.e001985.17","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/apt.15484","article-title":"Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases","volume":"50","author":"Singh","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/jgh.16518","article-title":"Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease","volume":"39","author":"Steenholdt","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.19","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn\u2019s Disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.20","first-page":"758","article-title":"Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease","volume":"26","author":"Ehrenberg","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2025122521050961000_12.1.e001985.21","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn\u2019s Disease: A Multicenter Study","volume":"15","author":"Fumery","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025122521050961000_12.1.e001985.22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coph.2020.09.002","article-title":"Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?","volume":"55","author":"Alsoud","year":"2020","journal-title":"Curr Opin Pharmacol"},{"key":"2025122521050961000_12.1.e001985.23","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1016\/j.cgh.2023.01.004","article-title":"Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study","volume":"21","author":"Wang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cgh.2020.02.033","article-title":"Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn\u2019s Disease Likely to Achieve Endoscopic and Biochemical Remission","volume":"19","author":"Han\u017eel","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.25","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1016\/j.cgh.2019.11.059","article-title":"Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.26","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.16551","article-title":"Higher concentrations of cytokine blockers are needed to obtain small bowel mucosal healing during maintenance therapy in Crohn\u2019s disease","volume":"54","author":"Takenaka","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.27","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-021-01946-8","article-title":"Ustekinumab trough concentration affects clinical and endoscopic outcomes in patients with refractory Crohn\u2019s disease: a Chinese real-world study","volume":"21","author":"Yao","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.28","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/MEG.0000000000002275","article-title":"Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn\u2019s disease","volume":"33","author":"Han\u017eel","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12876-022-02271-4","article-title":"Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn\u2019s disease","volume":"22","author":"Hirayama","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.30","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MCG.0000000000001978","article-title":"Ustekinumab Drug Levels and Outcomes in Inflammatory Bowel Disease","volume":"59","author":"Petrov","year":"2024","journal-title":"J Clin Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1751-2980.13264","article-title":"Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab","volume":"25","author":"Saleh","year":"2024","journal-title":"J Dig Dis"},{"key":"2025122521050961000_12.1.e001985.32","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122521050961000_12.1.e001985.33","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s10620-019-05570-1","article-title":"Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases","volume":"64","author":"Yarur","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2025122521050961000_12.1.e001985.34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14548"},{"key":"2025122521050961000_12.1.e001985.35","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/2050640619840211","article-title":"Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease","volume":"7","author":"Han\u017eel","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2025122521050961000_12.1.e001985.36","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn\u2019s Disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology"},{"key":"2025122521050961000_12.1.e001985.37","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz151"},{"key":"2025122521050961000_12.1.e001985.38","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1177\/2050640619873784","article-title":"Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease","volume":"7","author":"Guidi","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"2025122521050961000_12.1.e001985.39","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ecco-jcc\/jjz041","article-title":"Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease","volume":"13","author":"Ungaro","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2025122521050961000_12.1.e001985.40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"2025122521050961000_12.1.e001985.41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/ecco-jcc\/jjad015","article-title":"Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study","volume":"17","author":"Verstockt","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2025122521050961000_12.1.e001985.42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2019.08.061","article-title":"The Simplified Magnetic Resonance Index of Activity (MARIA) for Crohn\u2019s Disease Is Strongly Correlated With the MARIA and Clermont Score: An External Validation","volume":"158","author":"Williet","year":"2020","journal-title":"Gastroenterology"},{"key":"2025122521050961000_12.1.e001985.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpge.2015.08.004"},{"key":"2025122521050961000_12.1.e001985.44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/00365521.2021.2002397","article-title":"A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients\u2019 and physicians\u2019 preferences and adherence","volume":"57","author":"Christensen","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.45","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s41669-019-0121-8","article-title":"Remote Monitoring of Patient-Reported Outcomes in Ulcerative Colitis: A Prospective Real-World Pilot Study","volume":"3","author":"Sebastian","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"2025122521050961000_12.1.e001985.46","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","article-title":"The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn\u2019s Disease: Results From the SUCCESS Consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2025122521050961000_12.1.e001985.47","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1093\/ibd\/izac149","article-title":"Clinical, Endoscopic, and Radiological Effectiveness of Ustekinumab in Bio-na\u00efve Versus Bio-experienced Patients With Crohn\u2019s Disease: Real-world Experience From a Large Canadian Center","volume":"29","author":"Sedano","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"2025122521050961000_12.1.e001985.48","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.49","unstructured":"use, C.f.m.p.f.h . Guideline on the choice of the non-inferiority margin. 2005. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-choice-non-inferiority-margin_en.pdf"},{"key":"2025122521050961000_12.1.e001985.50","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and Anti-Tumour Necrosis Factor \u03b1 Real-World Outcomes in Biologic-Na\u00efve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2025122521050961000_12.1.e001985.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1480-0"},{"key":"2025122521050961000_12.1.e001985.52","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.14167","article-title":"One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study","volume":"46","author":"Amiot","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122521050961000_12.1.e001985.53","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40262-023-01274-y","article-title":"Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data","volume":"62","author":"Kluwe","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"2025122521050961000_12.1.e001985.54","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/bcp.14648","article-title":"Quantitative relationship between infliximab exposure and inhibition of C-reactive protein synthesis to support inflammatory bowel disease management","volume":"87","author":"Grisic","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2025122521050961000_12.1.e001985.55","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy222.614","article-title":"P490 A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis","volume":"13","author":"Rosario","year":"2019","journal-title":"Journal of Crohn\u2019s and Colitis"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T05:05:26Z","timestamp":1766725526000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,25]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjgast-2025-001985"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001985","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}